Exploring Protein A Immunoadsorption for Autoimmune Hemolytic Anemia with Hyper-IgG4emia

Area of Science:

• Hematology
• Immunology
• Internal Medicine

Background:

• Autoimmune hemolytic anemia (AIHA) involves autoantibodies against red blood cells, with subtypes including IgG1, IgG2, IgG3, and IgG4.
• High IgG4 levels in AIHA are uncommon and can be associated with poor treatment response.
• Conventional treatments like steroids and immunosuppressants may not be effective for all AIHA patients.

Purpose of the Study:

• To report a case of AIHA with high IgG4 levels that was refractory to standard treatment.
• To evaluate the efficacy of protein A immunosorbent therapy as an alternative treatment for AIHA.

Main Methods:

• A 60-year-old female patient with AIHA, high IgG4, and poor response to methylprednisolone and cyclophosphamide was treated with protein A immunoadsorption therapy.
• The patient received 4 sessions of protein A immunosorbent therapy in combination with the previous regimen.
• Clinical and laboratory parameters were monitored before, during, and after treatment.

Main Results:

• The patient showed significant clinical improvement, with reduced malaise and jaundice.
• Hemoglobin levels increased from 76 g/L to 136 g/L.
• IgG4 levels decreased from 12.4 g/L to 6.72 g/L after treatment.

Conclusions:

• Protein A immunosorbent therapy can be an effective treatment option for patients with AIHA, particularly those with high IgG4 levels who do not respond well to conventional therapies.
• This case suggests protein A immunoadsorption therapy as a viable alternative for refractory AIHA.
• Further studies are warranted to confirm the role of protein A immunosorbent therapy in AIHA management.